GENT, Belgium--(BUSINESS WIRE)--Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc.
Treating an Underdiagnosed Disease Surveying the Current Treatment Landscape Emerging Drugs Options for Difficult-to-Treat Patients References Approximately 10% of this drug is excreted in the urine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results